Navigation Links
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Date:8/30/2007

pleting enrollment in the two remaining, planned Phase III efficacy trials of IV acetaminophen by the end of 2007. Additionally, Cadence's licensor for IV acetaminophen, Bristol-Myers Squibb Company, is conducting a randomized trial of IV acetaminophen for marketing purposes in Europe in patients undergoing total hip replacement surgery. Cadence expects that data from this trial may be available in 2008; however, Cadence does not plan to rely on this clinical trial as a pivotal efficacy study for its New Drug Application (NDA) submission.

Assuming successful completion of the planned clinical trials, Cadence expects to submit a 505(b)(2) NDA to the U.S. Food and Drug Administration in the second half of 2008 requesting marketing approval of IV acetaminophen for acute pain and fever in adults and children.

About IV Acetaminophen

IV acetaminophen is a proprietary, intravenous formulation of acetaminophen. In oral form, acetaminophen is the most widely used medication in history for the treatment of pain and fever in the United States. Before the development of this intravenous formulation of acetaminophen, poor stability in aqueous solutions and inadequate solubility had prevented the development of an intravenous dosage form. IV acetaminophen has been previously studied in six completed Phase III trials, and Bristol-Myers Squibb has marketed the product since mid-2002 in Europe, where over 200 million vials of the drug have been sold since launch and it is the market leader among all injectable analgesics. In the United States, opioids and ketorolac (a non steroidal anti-inflammatory drug), are the only intravenous analgesics currently available to treat acute post-operative pain and are associated with significant adverse side effects.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... NEW YORK, Feb. 9, 2011 Reportlinker.com announces ... in its catalogue: European Markets ... http://www.reportlinker.com/p0377966/European-Markets-for-Spinal-Implants-and-VCF-2011.html iData,s comprehensive ... report is the industry leading research report for ...
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... chairman and chief executive officer, is scheduled to participate ... week. Details of the events are as follows:Tuesday, February ... Investor ConferencePanel Topic:  "Rheumatoid Arthritis: the Real Joint Problem"Tuesday, ...
Cached Medicine Technology:Reportlinker Adds European Markets for Spinal Implants and VCF 2011 2Rigel Announces Participation at Two Investor Conferences 2
(Date:12/24/2014)... News) -- Adults who experienced childhood abuse or ... suggests a study published online Dec. 24 in ... can have long-lasting effects, like associated medical and ... Dawn Buse, director of behavioral medicine at Montefiore ... a journal news release. "When managing patients ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... Teens are more likely to start smoking or drinking ... disorder (ADHD) or conduct disorder, new research suggests. ... about the risk of substance use as [these] children ... director at Cincinnati Pediatric Research Group, which is part ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... (ADA) call for giving the cholesterol-lowering drugs known as statins ... These new standards bring the association in line with ... also recommend giving low- or high-dose statins to all people ... "We agree that the decision to start a statin should ...
(Date:12/24/2014)... 2014 For chic ladies, new fashionable outfits ... part of their Holiday Wish List, Angeldress.co.uk has ... ways to accent ladies’ holiday wardrobe by launching a promotion ... all over the discount of 80% off, like a cheap ... ship. The company’s chic wedding dresses are among the hottest ...
(Date:12/24/2014)... December 24, 2014 Dr. Svetlana Gomer, ... across the nation gathered with US Marines on November ... raise funds for the Toys for Tots Literacy Program. ... thousands of new books and audio books for the ... underprivileged children this Christmas. It represents another major strike ...
Breaking Medicine News(10 mins):Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... Anaemia, a killer horse disease, is not about to deter ... no bones that the show will go on// , despite ... ,Nine horses have been fatally hit by EIA, ... positive for the disease. Show director Gerry McAuliffe confirmed that ...
... years, 50 million American women will be in menopause. ... use of synthetic hormone replacement// therapy (HRT) in a ... left many women and physicians uncertain about the safety ... (“natural”) hormone replacement therapy (nBHRT) has been proposed by ...
... of them women, were taken ill after inhaling fumes ... Bolangir district// , official said Thursday. ,The agricultural ... a field at Khairmal village, some 15 km from ... medical officer Sarada Prasad Mishra told IANS on phone. ...
... new study in patients with type 2 diabetes demonstrate ... chromium picolinate// , in combination with a common oral ... than the oral anti-diabetic agent alone. ,The ... (PBRC) and the University of Vermont College of Medicine, ...
... The tragic drug trial that left six volunteers seriously ill ... University researchers are collaborating with scientists from the drugs firm ... patients are exposed to a tiny amount of the drug ... in the earlier drug trial. , ,"We can monitor ...
... Economy has shown that in utero health has a great ... study is important because of its ramifications on health programs ... that can have far reaching impact in adulthood, much more ... purposes is that whereas heredity is immutable, congenital characteristics are ...
Cached Medicine News:Health News:Bio-Identical Hormone Replacement Therapy 2Health News:Bio-Identical Hormone Replacement Therapy 3Health News:Supplementation with Chromium Picolinate Improves Glycemic Control 2Health News:Personal Growth and Success Dependent on Prenatal Health 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: